Prophase Labs ( (PRPH) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
ProPhase Labs, Inc. has filed a Form 12b-25 to notify investors that it will delay its Quarterly Report on Form 10-Q (Quarter Report) for the period ended March 31, 2026. The filing highlights that the company is also behind on its Annual Report on Form 10-K (Yearly Report) for the year ended December 31, 2025, signaling a backlog in its financial reporting cycle.
The primary reason for the delay is the additional time required to complete the year-end financial reporting process and finalize the Annual Report on Form 10-K (Yearly Report). Ongoing audit procedures by the company’s independent registered public accounting firm are still in progress, and management states that filing the 10-Q (Quarter Report) now would require unreasonable effort or expense.
ProPhase Labs indicates that it expects to file the delayed Quarterly Report on Form 10-Q (Quarter Report) within the standard grace period allowed under SEC rules. For quarterly reports, this means the company plans to submit the 10-Q (Quarter Report) no later than five calendar days after the original due date, following completion of the audit for the 2025 fiscal year and filing of the 10-K (Yearly Report).
The company states that it does not anticipate any significant change in results of operations versus the same quarter of the prior year. While no preliminary financial figures are provided, this statement serves as a forward-looking indication that management does not expect major surprises in the upcoming quarterly earnings, though final numbers remain subject to completion of the audit and normal closing adjustments.
ProPhase Labs emphasizes that it is working diligently with its auditors to finalize financial statements and related disclosures and to bring all SEC filings current. The notification is signed on behalf of the company by Ted Karkus, Chairman of the Board and Chief Executive Officer, dated May 15, 2026, underscoring executive-level responsibility for the late filing and ongoing compliance efforts.
Spark’s Take on PRPH Stock
According to Spark, TipRanks’ AI Analyst, PRPH is a Neutral.
The score is held down primarily by weak financial performance (sharp revenue contraction, persistent losses, and negative cash flows) and bearish trend signals (price below major moving averages with negative MACD). Potential upside catalysts from the earnings call and recent financing/listing developments provide some offset, but execution and liquidity/dilution risks remain material.
To see Spark’s full report on PRPH stock, click here.
More about Prophase Labs
ProPhase Labs, Inc. is a U.S.-based company headquartered in Uniondale, New York. It is listed with SEC file number 000-21617 and operates in the healthcare and diagnostics space, historically known for consumer health products and, more recently, lab services.
Average Trading Volume: 179,825
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.14M
For a thorough assessment of PRPH stock, go to TipRanks’ Stock Analysis page.